Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gusacitinib (Primary)
  • Indications Eczema
  • Focus Therapeutic Use
  • Sponsors Asana BioSciences

Most Recent Events

  • 22 Apr 2023 Results of a Randomized Phase 2 Study assessing efficacy and safety published in the Journal of the American Academy of Dermatology
  • 22 Apr 2021 According to an Asana BioSciences media release, positive results from this study will be presented in a late-breaking research program at the American Academy of Dermatology Virtual Meeting (AAD VMX 2021).
  • 20 Oct 2020 According to an Asana BioSciences Media Release, gusacitinib was also effective in patients with chronic foot eczema and atopic dermatitis (as measured by vIGA in CHE patients who also had AD involvement) in this study and it demonstrated significant improvement in overall work productivity impairment. These results will be presented at a future date.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top